Zhi Tong Cai Jing·2025-08-28 11:07Core Viewpoint - Shanghai Pharmaceuticals (02607) reported a mid-year performance for 2025, showing a slight increase in revenue but a significant rise in net profit due to accounting changes [1] Financial Performance - The company's operating revenue was approximately 141.59 billion, reflecting a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders was about 4.46 billion, marking a substantial year-on-year increase of 51.56% [1] - Basic earnings per share stood at 1.2 yuan [1] Special Accounting Changes - The increase in net profit was primarily attributed to a one-time special gain resulting from the change in accounting treatment of Hutchison Whampoa from equity method accounting to subsidiary accounting [1] - Excluding this one-time special gain, the net profit attributable to shareholders was 2.78 billion, which represents a year-on-year decline of 2.06% [1]